CNS Pharmaceuticals Q3 2023 Earnings Report $0.11 +0.01 (+5.41%) (As of 12/26/2024 05:41 PM ET) Earnings HistoryForecast CNS Pharmaceuticals EPS ResultsActual EPS-$54.00Consensus EPS -$86.50Beat/MissBeat by +$32.50One Year Ago EPSN/ACNS Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACNS Pharmaceuticals Announcement DetailsQuarterQ3 2023Date11/14/2023TimeAfter Market ClosesConference Call ResourcesCNSP Earnings History BITCOIN (Ad)Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this...Watch this short video CNS Pharmaceuticals Earnings HeadlinesCNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual MeetingNovember 20, 2024 | theglobeandmail.comCNS Pharmaceuticals sees cash runway through 2Q25November 16, 2024 | markets.businessinsider.comThe Current Gold Supercycle ExplainedIf you haven’t been paying attention to gold… you’re missing out! Over the last year, it’s been on a tear… And the same guy who called this massive rally on December 7th 2023 also says we’re just getting warmed up! Inside, you’ll learn the “why” behind this massive rally and the key reasons Geof believes the gold supercycle is just beginning! Plus he’ll give you some insights on how to actively trade this generational opportunity. While we cannot promise future returns or protection against losses, these insights can help you make informed decisions. Read the eBook NowDecember 27, 2024 | DTI (Ad)CNS Pharmaceuticals: Financial Results and Strategic MovesNovember 16, 2024 | markets.businessinsider.comCNS Pharmaceuticals (NASDAQ: CNSP) Highlights Berubicin’s Potential During KOL Connect EventNovember 5, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Secures $3 Million in Registered Direct OfferingOctober 25, 2024 | theglobeandmail.comSee More CNS Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email. Email Address About CNS PharmaceuticalsCNS Pharmaceuticals (NASDAQ:CNSP), a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.View CNS Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
